Evidence map›Paper›PMID 33929716›Full record

ReviewDrugs2021

Preclinical and Clinical Characteristics of the Trichuricidal Drug Oxantel Pamoate and Clinical Development Plans: A Review.

Marta S Palmeirim, Sabine Specht, Ivan Scandale, Irene Gander-Meisterernst, Monika Chabicovsky, Jennifer Keiser

Open access · hybridAbstract readReview
In one paragraph

Review in Drugs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Marta S PalmeirimDepartment of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, P.O. Box, 4002, Basel, Switzerland.ORCID http://orcid.org/0000-0002-4709-2489
Sabine SpechtDrugs for Neglected Diseases Initiative, 15 Chemin Louis-Dunant, 1202, Geneva, Switzerland.ORCID http://orcid.org/0000-0002-5351-5812
Ivan ScandaleDrugs for Neglected Diseases Initiative, 15 Chemin Louis-Dunant, 1202, Geneva, Switzerland.ORCID http://orcid.org/0000-0003-4242-9289
Irene Gander-MeisterernstRegulatory Strategies, Schulstrasse 10, 48149, Münster, Germany.
Monika ChabicovskyMC Toxicology Consulting GmbH, Siebensterngasse 31/8, 1070, Vienna, Austria.
Jennifer KeiserDepartment of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, P.O. Box, 4002, Basel, Switzerland. jennifer.keiser@swisstph.ch.ORCID http://orcid.org/0000-0003-0290-3521
Drugs for Neglected Diseases Initiative · CHSwiss Tropical and Public Health Institute · CHHerry Consult (Austria) · AT

Funding

Horizon 2020 Framework Programme 815628
6 · The paper itself

Abstract

Soil-transmitted helminths (Ascaris lumbricoides, hookworm and Trichuris trichiura) infect about one-fifth of the world's population. The currently available drugs are all highly efficacious against A. lumbricoides. However, they are only moderately efficacious against hookworm and poorly efficacious against T. trichiura. Oxantel, a tetrahydropyrimidine derivative discovered in the 1970s, has recently been brought back to our attention given its high efficacy against T. trichiura infections (estimated 76% cure rate and 85% egg reduction rate at a 20 mg/kg dose). This review summarizes the current knowledge on oxantel pamoate and its use against T. trichiura infections in humans. Oxantel pamoate acts locally in the human gastrointestinal tract and binds to the parasite's nicotinic acetylcholine receptor (nAChR), leading to a spastic paralysis of the worm and subsequent expulsion. The drug is metabolically stable, shows low permeability and low systemic bioavailability after oral use. Oxantel pamoate was found to be safe in humans, with only a few mild adverse events reported. Several clinical trials have investigated the efficacy of this drug against T. trichiura and suggest that oxantel pamoate is more efficacious against T. trichiura than the currently recommended drugs, which makes it a strong asset to the depleted drug armamentarium and could help delay or even prevent the development of resistance to existing drugs. We highlight existing data to support the use of oxantel pamoate against T. trichiura infections.

Indexed as

AnimalsAntinematodal AgentsDose-Response Relationship, DrugDrug InteractionsHookworm InfectionsHumansPyrantel PamoateTrichurisAntinematodal Agentsoxantel pamoatePyrantel Pamoate

Identifiers

PMID33929716
PMCPMC8144136
OpenAlexW3159898178

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.